Modelled DT Structure
Method: homology modeling
Template PDB: 6UY0_A
Identity: 57.19%
Minimized Score: -3311.772 kcal/mol
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0012 | ||||
Gene Name | ABCC3 | ||||
Protein Name | Multidrug resistance-associated protein 3 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method: homology modeling Template PDB: 6UY0_A Identity: 57.19% Minimized Score: -3311.772 kcal/mol Detail: Structure Info |
||||
Synonyms | ABC31; ABCC3; ATP-binding cassette sub-family C member 3; CMOAT2; Canalicular multispecific organic anion transporter 2; EST90757; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D | ||||
DT Family | ATP-Binding Cassette (ABC) Superfamily | ||||
Drug Conjugate Transporter (DCT) Family (ABCC) | |||||
Tissue Specificity | Mainly expressed in the liver. Also expressedin small intestine, colon, prostate, testis, brain and at a lowerlevel in the kidney. | ||||
Function | This transporter may act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes. | ||||
Disease(s) | Allergic rhinitis [ICD-11: CA08.0] | ||||
Colorectal cancer [ICD-11: 2B91] | |||||
Hypercholesterolemia [ICD-11: 5C80.0] | |||||
Kaposi's sarcoma [ICD-11: 2B57] | |||||
Leukemia [ICD-11: 2A60-2B33] | |||||
Chronic pain [ICD-11: MG30] | |||||
Endogenous Substrate(s) | Canicular organoanions; GSH-X; Sulfate-X; Bile acids; Bilirubin-glucuronides; Epoposide glucuronide; Estradiol 17-beta-D-glucuronide; Glycocholate; Leukotriene C4 | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(α) Microbiota Influence of This DT |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
(ε) Exogenous Modulation of This DT |
|||||
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
(β) Inter-species Structural Differences |
|||||
(γ) Outward/inward-facing Conformation |
|||||
(δ) Xenobiotics-regulated Structural Variability |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(α) Genetic Polymorphisms of This DT |
|||||
(β) Disease-specific Protein Abundances of This DT |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
Molecular Transporting Profile of This DT | |||||
Full List of Drug(s) Transported by This DT |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 17 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Cefadroxil
|
Approved | Drug Info | Gram-positive & negative bacteria infections | 1A00-1H0Z | [1] |
Dehydroepiandrosterone sulfate
|
Approved | Drug Info | Dyspareunia | GA12 | [2] |
Efavirenz
|
Approved | Drug Info | Human immunodeficiency virus infection | 1C62.Z | [3] |
Etoposide
|
Approved | Drug Info | Testicular cancer | 2C80 | [4] |
Etravirine
|
Approved | Drug Info | Human immunodeficiency virus infection | 1C62.Z | [5] |
Ezetimibe
|
Approved | Drug Info | Hypercholesterolemia | 5C80.0 | [6] |
Fexofenadine
|
Approved | Drug Info | Allergic rhinitis | CA08.0 | [7] |
Fluorouracil
|
Approved | Drug Info | Stomach cancer | 2B72 | [8] |
Folic acid
|
Approved | Drug Info | Vitamin deficiency | 5B55-5B7Z | [9] |
Glibenclamide
|
Approved | Drug Info | Diabetes | 5A10-5A14 | [10] |
Glycyrrhizin
|
Approved | Drug Info | Hepatitis C virus infection | 1E50.2, 1E51.1 | [11] |
Leucovorin
|
Approved | Drug Info | Colorectal cancer | 2B91 | [9] |
Methotrexate
|
Approved | Drug Info | Leukemia | 2A60-2B33 | [12] |
Morphine
|
Approved | Drug Info | Chronic pain | MG30 | [13] |
Paclitaxel
|
Approved | Drug Info | Breast cancer | 2C60-2C6Z | [14] |
Technetium (99MTC) mebrofenin
|
Approved | Drug Info | Imaging of liver and gallbladder | XD47Y1 | [15] |
Teniposide
|
Approved | Drug Info | Acute lymphoblastic leukemia | 2B33.0 | [16] |
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 4 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Glycocholic acid
|
Phase 3 | Drug Info | Bile acid synthesis defect | 5C52.11 | [17] |
Trabectedin
|
Phase 3 | Drug Info | Ovarian cancer | 2C73 | [18] |
Cholyl lysyl fluorescein
|
Phase 2 | Drug Info | Hepatitis virus infection | 1E5Z | [19] |
Glutathione-S-S-glutathione
|
Phase 2 | Drug Info | Ovarian cancer | 2C73 | [20] |
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 5 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Epipodophyllotoxins
|
Preclinical | Drug Info | Molluscum contagiosum infection | 1.00E+76 | [16] |
Monomethyl-auristatin-E
|
Preclinical | Drug Info | Cancer | 2A00-2F9Z | [14] |
Scutellarin
|
Preclinical | Drug Info | Cerebrovascular ischaemia | 8B1Z | [21] |
Sodium taurocholate
|
Preclinical | Drug Info | Type 2 diabetes | 5A11 | [22] |
Taurocholic acid
|
Terminated | Drug Info | Type 2 diabetes | 5A11 | [22] |
Endogenous Metabolites (EMs) Handled by This DT |
|||||
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 1 EMs in Total | ||||
EM Name | PubChem CID | Detail | Experimental Material | Ref | |
Glucuronide | EM Info | Identified using Mrp3 knockout mice | [23] | ||
Drug-DT Affinity Assessed by Cell Line |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 7 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Cefadroxil | Approved | Drug Info | Spodoptera frugiperda 21 (Sf21) cells-MRP3 | Km = 2.5 microM | [1] |
Etoposide | Approved | Drug Info | Spodoptera frugiperda (Sf9) cells-MRP3 | Km = 11.4 microM | [16] |
Folic acid | Approved | Drug Info | Human embryonic kidney cells (HEK293)-MRP3 | Km = 1960 microM | [9] |
Leucovorin | Approved | Drug Info | Human embryonic kidney cells (HEK293)-MRP3 | Km = 1740 microM | [9] |
Methotrexate | Approved | Drug Info | Breast carcinoma cell line (MCF7)-MRP3 | Km = 910 microM | [12] |
Methotrexate | Approved | Drug Info | Human embryonic kidney cells (HEK293)-MRP3 | Km = 620 microM | [9] |
Methotrexate | Approved | Drug Info | Human embryonic kidney cells (HEK293)-MRP3 | Km = 776 microM | [24] |
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 4 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Sodium taurocholate | Preclinical | Drug Info | Human embryonic kidney cells (HEK293)-MRP3 | Km = 30 microM | [22] |
Estradiol-17beta-glucuronide | Investigative | Drug Info | Human embryonic kidney cells (HEK293)-MRP3 | Km = 25.6 microM | [24] |
Estradiol-17beta-glucuronide | Investigative | Drug Info | Human embryonic kidney cells (HEK293)-MRP3 | Km = 29 microM | [22] |
Estradiol-17beta-glucuronide | Investigative | Drug Info | Spodoptera frugiperda (Sf9) cells-MRP3 | Km = 17.7 microM | [16] |
References | |||||
1 | Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. | ||||
2 | Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006 Apr;27(5):447-86. | ||||
3 | Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50. | ||||
4 | Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30. | ||||
5 | Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. 2011 Mar;55(3):1282-4. | ||||
6 | Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702. | ||||
7 | Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83. | ||||
8 | ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. | ||||
9 | Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. | ||||
10 | Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. | ||||
11 | The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 2007 Dec;31(6):1465-72. | ||||
12 | Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. | ||||
13 | Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73. | ||||
14 | Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9. | ||||
15 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | ||||
16 | Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. | ||||
17 | Measurement of transport activities of bile acids in human multidrug resistance-associated protein 3 using liquid chromatography-tandem mass spectrometry. Anal Sci. 2010;26(3):317-23. | ||||
18 | ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity. Clin Cancer Res. 2009 Dec 15;15(24):7616-7623. | ||||
19 | The emerging role of transport systems in liver function tests. Eur J Pharmacol. 2012 Jan 30;675(1-3):1-5. | ||||
20 | MRP2 and 3 in health and disease. Cancer Lett. 2006 Mar 8;234(1):51-61. | ||||
21 | Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20. | ||||
22 | Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000. | ||||
23 | Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol. 2006 Apr;44(4):768-75. | ||||
24 | Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000 Sep 1;60(17):4779-84. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.